U.S. Markets closed

Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

Allison DeAngelis
Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

Errant Gene Therapeutics claims in a new lawsuit that local venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could obtain a key part of its intellectual property.